-
1
-
-
57049146698
-
-
Available from:, Last accessed 2008 May 21
-
Zyprexa. Anon. 2008. Available from: http://pi.lilly.com/us/ zyprexa-pi.pdf [Last accessed 2008 May 21]
-
(2008)
-
-
-
2
-
-
0023254675
-
Dopamine receptors and the dopamine hypothesis of schizophrenia
-
Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987;1(2):133-52
-
(1987)
Synapse
, vol.1
, Issue.2
, pp. 133-152
-
-
Seeman, P.1
-
3
-
-
0036221550
-
Atypical antipsychotics: Mechanism of action
-
Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002;47(1):27-38
-
(2002)
Can J Psychiatry
, vol.47
, Issue.1
, pp. 27-38
-
-
Seeman, P.1
-
4
-
-
0003841783
-
-
3rd edition. Cambridge, UK: Cambridge University Press;
-
Stahl SM. Stahl's Essential Psychopharmacology. 3rd edition. Cambridge, UK: Cambridge University Press; 2008
-
(2008)
Essential Psychopharmacology
-
-
Stahl's, S.S.M.1
-
5
-
-
33644684681
-
Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus
-
Matsui-Sakata A, Ohtani H, Sawada Y. Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet 2005;20(5):368-78
-
(2005)
Drug Metab Pharmacokinet
, vol.20
, Issue.5
, pp. 368-378
-
-
Matsui-Sakata, A.1
Ohtani, H.2
Sawada, Y.3
-
6
-
-
23144441853
-
The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment
-
Reynolds GP, Templeman LA, Zhang ZJ. The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Prog Neuropsychopharmacol Biol Psychiatry 2005;29(6):1021-8
-
(2005)
Prog Neuropsychopharmacol Biol Psychiatry
, vol.29
, Issue.6
, pp. 1021-1028
-
-
Reynolds, G.P.1
Templeman, L.A.2
Zhang, Z.J.3
-
7
-
-
38349190623
-
Sex, race, and smoking impact olanzapine exposure
-
Bigos KL, Pollock BG, Coley KC, et al. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol 2008;48(2):157-65
-
(2008)
J Clin Pharmacol
, vol.48
, Issue.2
, pp. 157-165
-
-
Bigos, K.L.1
Pollock, B.G.2
Coley, K.C.3
-
8
-
-
45249085941
-
An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia
-
Lauriello J, Lambert T, Andersen S, et al. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry 2008;69(5):790-9
-
(2008)
J Clin Psychiatry
, vol.69
, Issue.5
, pp. 790-799
-
-
Lauriello, J.1
Lambert, T.2
Andersen, S.3
-
9
-
-
57049114182
-
-
Briefing Document for Olanzapine Pamoate (OP) Depot.United States Food and Drug Administration Pharmacological Drugs Advisory Committee. 2008 February 6. Available from: http://www.fda.gov/OHRMS/DOCKETS/AC/08/ briefing/2008-4338bl-03-Lilly.pdf [Last accessed 2008 June 8]
-
Briefing Document for Olanzapine Pamoate (OP) Depot.United States Food and Drug Administration Pharmacological Drugs Advisory Committee. 2008 February 6. Available from: http://www.fda.gov/OHRMS/DOCKETS/AC/08/ briefing/2008-4338bl-03-Lilly.pdf [Last accessed 2008 June 8]
-
-
-
-
10
-
-
36949008116
-
D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: An open-label study in patients with schizophrenia
-
Mamo D, Kapur S, Keshavan M, et al. D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. Neuropsychopharmacology 2008;33(2):298-304
-
(2008)
Neuropsychopharmacology
, vol.33
, Issue.2
, pp. 298-304
-
-
Mamo, D.1
Kapur, S.2
Keshavan, M.3
-
11
-
-
0038653525
-
A meta-analysis of the efficacy of second-generation antipsychotics
-
Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60(6):553-64
-
(2003)
Arch Gen Psychiatry
, vol.60
, Issue.6
, pp. 553-564
-
-
Davis, J.M.1
Chen, N.2
Glick, I.D.3
-
12
-
-
25144456112
-
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
-
Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209-23
-
(2005)
N Engl J Med
, vol.353
, Issue.12
, pp. 1209-1223
-
-
Lieberman, J.A.1
Stroup, T.S.2
McEvoy, J.P.3
-
13
-
-
40949142200
-
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: An open randomised clinical trial
-
Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008;371(9618):1085-97
-
(2008)
Lancet
, vol.371
, Issue.9618
, pp. 1085-1097
-
-
Kahn, R.S.1
Fleischhacker, W.W.2
Boter, H.3
-
14
-
-
33749321169
-
Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)
-
Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch of Gen Psychiatry 2006;63(10):1079-87
-
(2006)
Arch of Gen Psychiatry
, vol.63
, Issue.10
, pp. 1079-1087
-
-
Jones, P.B.1
Barnes, T.R.2
Davies, L.3
-
15
-
-
38049002952
-
Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: A quantitative review of efficacy and safety
-
Citrome L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin Psychiatry 2007;68(12):1876-85
-
(2007)
J Clin Psychiatry
, vol.68
, Issue.12
, pp. 1876-1885
-
-
Citrome, L.1
-
16
-
-
15944379171
-
Toward convergence in the medication treatment of bipolar disorder and schizophrenia
-
Citrome L, Goldberg JF, Stahl SM. Toward convergence in the medication treatment of bipolar disorder and schizophrenia. Harv Rev Psychiatry 2005;13(1):28-42
-
(2005)
Harv Rev Psychiatry
, vol.13
, Issue.1
, pp. 28-42
-
-
Citrome, L.1
Goldberg, J.F.2
Stahl, S.M.3
-
17
-
-
0032919745
-
Olanzapine versus placebo in the treatment of acute mania: Olanzapine HGEH Study Group
-
Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania: Olanzapine HGEH Study Group. Am J Psychiatry 1999;156(5):702-9
-
(1999)
Am J Psychiatry
, vol.156
, Issue.5
, pp. 702-709
-
-
Tohen, M.1
Sanger, T.M.2
McElroy, S.L.3
-
18
-
-
0033863937
-
Efficacy of olanzapine in acute bipolar mania: A double-blind, placebo-controlled study. The Olanzipine HGGW Study Group
-
Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry 2000;57(9):841-9
-
(2000)
Arch Gen Psychiatry
, vol.57
, Issue.9
, pp. 841-849
-
-
Tohen, M.1
Jacobs, T.G.2
Grundy, S.L.3
-
19
-
-
0041977102
-
Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: A 47-week study
-
Tohen M, Ketter TA, Zarate CA, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 2003;160(7):1263-71
-
(2003)
Am J Psychiatry
, vol.160
, Issue.7
, pp. 1263-1271
-
-
Tohen, M.1
Ketter, T.A.2
Zarate, C.A.3
-
20
-
-
10744220918
-
Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression
-
Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60(11):1079-88
-
(2003)
Arch Gen Psychiatry
, vol.60
, Issue.11
, pp. 1079-1088
-
-
Tohen, M.1
Vieta, E.2
Calabrese, J.3
-
21
-
-
33747169047
-
A 7-week, randomized, double-blind trial of olanzapine/fluoxerine combination versus lamotrigine in the treatment of bipolar I depression
-
Brown EB, McElroy SL, Keck PEJ, et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxerine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 2003;67(7):1025-33
-
(2003)
J Clin Psychiatry
, vol.67
, Issue.7
, pp. 1025-1033
-
-
Brown, E.B.1
McElroy, S.L.2
Keck, P.E.J.3
-
22
-
-
0032751075
-
Antipsychotic-induced weight gain: A comprehensive research synthesis
-
Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156(11):1686-96
-
(1999)
Am J Psychiatry
, vol.156
, Issue.11
, pp. 1686-1696
-
-
Allison, D.B.1
Mentore, J.L.2
Heo, M.3
-
23
-
-
0036936014
-
A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder
-
Zajecka JM, Weisler R, Sachs G, et al. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2002;63(12):1148-55
-
(2002)
J Clin Psychiatry
, vol.63
, Issue.12
, pp. 1148-1155
-
-
Zajecka, J.M.1
Weisler, R.2
Sachs, G.3
-
24
-
-
0036274760
-
Olanzapine versus divalproex in the treatment of acute mania
-
Tohen M, Baker RW, Altshuler LL, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 2002;159(6):1011-7
-
(2002)
Am J Psychiatry
, vol.159
, Issue.6
, pp. 1011-1017
-
-
Tohen, M.1
Baker, R.W.2
Altshuler, L.L.3
-
25
-
-
10744221700
-
A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania
-
Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry 2003;60(12):1218-26
-
(2003)
Arch Gen Psychiatry
, vol.60
, Issue.12
, pp. 1218-1226
-
-
Tohen, M.1
Goldberg, J.F.2
Gonzalez-Pinto Arrillaga, A.M.3
-
26
-
-
33845636133
-
Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: A randomized, double-blind trial
-
Perlis RH, Baker RW, Zarate CA Jr, et al. Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial. J Clin Psychiatry 2006;67(11):1747-53
-
(2006)
J Clin Psychiatry
, vol.67
, Issue.11
, pp. 1747-1753
-
-
Perlis, R.H.1
Baker, R.W.2
Zarate Jr, C.A.3
-
27
-
-
26444456116
-
Olanzapine versus ziprasidone: Results of a 28-week double-blind study in patients with schizophrenia
-
Breier A, Berg PH, Thakore JH, et al. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry 2005;162(10):1879-87
-
(2005)
Am J Psychiatry
, vol.162
, Issue.10
, pp. 1879-1887
-
-
Breier, A.1
Berg, P.H.2
Thakore, J.H.3
-
28
-
-
33750614310
-
Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: A 52-week, open-label comparison with olanzapine
-
Chrzanowski WK, Marcus RN, Torbeyns A, et al. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology 2006;189(2):259-66
-
(2006)
Psychopharmacology
, vol.189
, Issue.2
, pp. 259-266
-
-
Chrzanowski, W.K.1
Marcus, R.N.2
Torbeyns, A.3
-
29
-
-
33747398701
-
Olanzapine and haloperidol in first episode psychosis: Two-year data
-
Green AI, Lieberman JA, Hamer RM, et al. Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr Res 2006;86(1-3):234-43
-
(2006)
Schizophr Res
, vol.86
, Issue.1-3
, pp. 234-243
-
-
Green, A.I.1
Lieberman, J.A.2
Hamer, R.M.3
-
30
-
-
33748743350
-
Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning
-
Kinon BJ, Noordsy DL, Liu-Seifert H, et al. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning. J Clin Psychopharmacol 2006;26(5):453-61
-
(2006)
J Clin Psychopharmacol
, vol.26
, Issue.5
, pp. 453-461
-
-
Kinon, B.J.1
Noordsy, D.L.2
Liu-Seifert, H.3
-
31
-
-
33746885198
-
Comparison of atypicals in first-episode psychosis: A randomized, 52-week comparison of olanzapine, quetiapine, and risperidone [abstract no. P.3.163]
-
Lieberman JA, McEvoy JP, Perkins DO, et al. Comparison of atypicals in first-episode psychosis: A randomized, 52-week comparison of olanzapine, quetiapine, and risperidone [abstract no. P.3.163]. Eur Neuropsychopharmacol 2005;15(3 Suppl):S526
-
(2005)
Eur Neuropsychopharmacol
, vol.15
, Issue.3 SUPPL.
-
-
Lieberman, J.A.1
McEvoy, J.P.2
Perkins, D.O.3
-
32
-
-
16644402581
-
A comparison of weight change during treatment with olanzapine or aripiprazole: Results from a randomized, double-blind study
-
McQuade RD, Stock E, Marcus R, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 2004;65(18 Suppl):47-56
-
(2004)
J Clin Psychiatry
, vol.65
, Issue.18 SUPPL.
, pp. 47-56
-
-
McQuade, R.D.1
Stock, E.2
Marcus, R.3
-
33
-
-
34147185609
-
Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine
-
Peuskens J, De Hert M, Mortimer A. Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine. Int Clin Psychopharmacol 2007;22(3):145-52
-
(2007)
Int Clin Psychopharmacol
, vol.22
, Issue.3
, pp. 145-152
-
-
Peuskens, J.1
De Hert, M.2
Mortimer, A.3
-
34
-
-
0345293130
-
Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: A randomized controlled trial
-
Rosenheck R, Perlick D, Bingham S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003;290(20):2693-702
-
(2003)
JAMA
, vol.290
, Issue.20
, pp. 2693-2702
-
-
Rosenheck, R.1
Perlick, D.2
Bingham, S.3
-
35
-
-
11144354711
-
Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone
-
Tohen M, Chengappa KN, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004;184:337-45
-
(2004)
Br J Psychiatry
, vol.184
, pp. 337-345
-
-
Tohen, M.1
Chengappa, K.N.2
Suppes, T.3
-
36
-
-
0030770872
-
Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
-
Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17(5):407-18
-
(1997)
J Clin Psychopharmacol
, vol.17
, Issue.5
, pp. 407-418
-
-
Tran, P.V.1
Hamilton, S.H.2
Kuntz, A.J.3
-
37
-
-
28644433423
-
Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol
-
Zipursky RB, Gu H, Green AI, et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry 2005;187:537-43
-
(2005)
Br J Psychiatry
, vol.187
, pp. 537-543
-
-
Zipursky, R.B.1
Gu, H.2
Green, A.I.3
-
38
-
-
21344437952
-
Olanzapine versus lithium in the maintenance treatment of bipolar disorder: A 12-month, randomized, double-blind, controlled clinical trial
-
Tohen M, Greil W, Calabrese JR, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005;162(7):1281-90
-
(2005)
Am J Psychiatry
, vol.162
, Issue.7
, pp. 1281-1290
-
-
Tohen, M.1
Greil, W.2
Calabrese, J.R.3
-
39
-
-
33646681652
-
A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms
-
Kinon BJ, Lipkovich I, Edwards SB, et al. A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. J Clin Psychopharmacol 2006;26(2):157-62
-
(2006)
J Clin Psychopharmacol
, vol.26
, Issue.2
, pp. 157-162
-
-
Kinon, B.J.1
Lipkovich, I.2
Edwards, S.B.3
-
40
-
-
57049143006
-
Patterns of antipsychotic-induced weight change: 3-year results from the intercontinental schizophrenia outpatient-health outcomes (IC-SOHO) study [abstract no. P.3.c.021]
-
Dossenbach M, Pachecho Z, Toledo D, et al. Patterns of antipsychotic-induced weight change: 3-year results from the intercontinental schizophrenia outpatient-health outcomes (IC-SOHO) study [abstract no. P.3.c.021]. Eur Neuropsychopharmacol 2006;16(4 Suppl):S407-8
-
(2006)
Eur Neuropsychopharmacol
, vol.16
, Issue.4 SUPPL.
-
-
Dossenbach, M.1
Pachecho, Z.2
Toledo, D.3
-
41
-
-
33846558834
-
Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: Observational versus randomized studies results
-
Haro JM, Suarez D, Novick D, et al. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol 2007;17(4):235-44
-
(2007)
Eur Neuropsychopharmacol
, vol.17
, Issue.4
, pp. 235-244
-
-
Haro, J.M.1
Suarez, D.2
Novick, D.3
-
42
-
-
0035108241
-
Long-term olanzapine treatment: Weight change and weight-related health factors in schizophrenia
-
Kinon BJ, Basson BR, Gilmore JA, et al. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001;62(2):92-100
-
(2001)
J Clin Psychiatry
, vol.62
, Issue.2
, pp. 92-100
-
-
Kinon, B.J.1
Basson, B.R.2
Gilmore, J.A.3
-
43
-
-
54449091993
-
Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: A randomized, double-blind, fixed dose study
-
Kinon BJ, Volavka J, Stauffer VL, et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed dose study. J Clin Psychopharmacol 2008;28(4):392-400
-
(2008)
J Clin Psychopharmacol
, vol.28
, Issue.4
, pp. 392-400
-
-
Kinon, B.J.1
Volavka, J.2
Stauffer, V.L.3
-
44
-
-
33744485015
-
Early predictors of substantial weight gain in bipolar patients treated with olanzapine
-
Lipkovich I, Citrome L, Perlis R, et al. Early predictors of substantial weight gain in bipolar patients treated with olanzapine. J Clin Psychopharmacol 2006;26(3):316-20
-
(2006)
J Clin Psychopharmacol
, vol.26
, Issue.3
, pp. 316-320
-
-
Lipkovich, I.1
Citrome, L.2
Perlis, R.3
-
45
-
-
46249092841
-
Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia
-
Kinon BJ, Chen L, Ascher-Svanum H, et al. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res 2008;102(1-3):230-40
-
(2008)
Schizophr Res
, vol.102
, Issue.1-3
, pp. 230-240
-
-
Kinon, B.J.1
Chen, L.2
Ascher-Svanum, H.3
-
46
-
-
54049091644
-
Schizophrenia, obesity, and antipsychotic medications: What can we do?
-
Citrome L, Vreeland B. Schizophrenia, obesity, and antipsychotic medications: what can we do? Postgrad Med 2008;120(2):18-33
-
(2008)
Postgrad Med
, vol.120
, Issue.2
, pp. 18-33
-
-
Citrome, L.1
Vreeland, B.2
-
47
-
-
0035146402
-
The continuing increase of diabetes in the US
-
Mokdad AH, Ford ES, Bowman BA, et al. The continuing increase of diabetes in the US. Diabetes Care 2001;24(2):412
-
(2001)
Diabetes Care
, vol.24
, Issue.2
, pp. 412
-
-
Mokdad, A.H.1
Ford, E.S.2
Bowman, B.A.3
-
48
-
-
33747024519
-
Incidence, prevalence, and surveillance for diabetes in New York State Psychiatric Hospitals, 1997-2004
-
Citrome L, Jaffe A, Levine J, et al. Incidence, prevalence, and surveillance for diabetes in New York State Psychiatric Hospitals, 1997-2004. Psychiatr Serv 2006;57(8):1132-9
-
(2006)
Psychiatr Serv
, vol.57
, Issue.8
, pp. 1132-1139
-
-
Citrome, L.1
Jaffe, A.2
Levine, J.3
-
49
-
-
0036020018
-
Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use
-
Regenold WT, Thapar RK, Marano C, et al. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 2002;70(1):19-26
-
(2002)
J Affect Disord
, vol.70
, Issue.1
, pp. 19-26
-
-
Regenold, W.T.1
Thapar, R.K.2
Marano, C.3
-
50
-
-
0027529974
-
Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): Relation to reduced fetal growth
-
Barker DJ, Hales CN, Fall CH, et al. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia 1993;36(1):62-7
-
(1993)
Diabetologia
, vol.36
, Issue.1
, pp. 62-67
-
-
Barker, D.J.1
Hales, C.N.2
Fall, C.H.3
-
51
-
-
0030021577
-
Schizophrenia after prenatal famine. Further evidence
-
Susser E, Neugebauer R, Hoek HW, et al. Schizophrenia after prenatal famine. Further evidence. Arch Gen Psychiatry 1996;53(1):25-31
-
(1996)
Arch Gen Psychiatry
, vol.53
, Issue.1
, pp. 25-31
-
-
Susser, E.1
Neugebauer, R.2
Hoek, H.W.3
-
52
-
-
0032977072
-
The unhealthy lifestyle of people with schizophrenia
-
Brown S, Birtwistle J, Roe L, et al. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999;29(3):697-701
-
(1999)
Psychol Med
, vol.29
, Issue.3
, pp. 697-701
-
-
Brown, S.1
Birtwistle, J.2
Roe, L.3
-
53
-
-
33646103388
-
Clustering of metabolic comorbidity in schizophrenia: A genetic contribution?
-
Gough SC, O'Donovan MC. Clustering of metabolic comorbidity in schizophrenia: a genetic contribution? J Psychopharmacol 2005;19(6 Suppl):47-55
-
(2005)
J Psychopharmacol
, vol.19
, Issue.6 SUPPL.
, pp. 47-55
-
-
Gough, S.C.1
O'Donovan, M.C.2
-
54
-
-
37049000576
-
Blood glucose and schizophrenia: A systematic review of prospective randomized clinical trials
-
Bushe CJ, Leonard BE. Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials. J Clin Psychiatry 2007;68(11):1682-90
-
(2007)
J Clin Psychiatry
, vol.68
, Issue.11
, pp. 1682-1690
-
-
Bushe, C.J.1
Leonard, B.E.2
-
55
-
-
0037315939
-
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics
-
Lindenmayer JP, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003;160(2):290-6
-
(2003)
Am J Psychiatry
, vol.160
, Issue.2
, pp. 290-296
-
-
Lindenmayer, J.P.1
Czobor, P.2
Volavka, J.3
-
56
-
-
4744338410
-
Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder
-
Simpson GM, Glick ID, Weiden PJ, et al. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry 2004;161(10):1837-47
-
(2004)
Am J Psychiatry
, vol.161
, Issue.10
, pp. 1837-1847
-
-
Simpson, G.M.1
Glick, I.D.2
Weiden, P.J.3
-
57
-
-
23344434378
-
Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia
-
Simpson GM, Weiden P, Pigott T, et al. Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. Am J Psychiatry 2005;162(8):1535-8
-
(2005)
Am J Psychiatry
, vol.162
, Issue.8
, pp. 1535-1538
-
-
Simpson, G.M.1
Weiden, P.2
Pigott, T.3
-
58
-
-
33750026127
-
Metabolic changes during 5 months treatment with olanzapine or risperidone: Preliminary results from randomized trial [abstract]
-
Smith RC, lindenmayer A, Buga A, et al. Metabolic changes during 5 months treatment with olanzapine or risperidone: preliminary results from randomized trial [abstract]. Schizophr Bull 2005;31(2):570
-
(2005)
Schizophr Bull
, vol.31
, Issue.2
, pp. 570
-
-
Smith, R.C.1
lindenmayer, A.2
Buga, A.3
-
59
-
-
33744964843
-
Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia
-
Wu RR, Zhao JP, Liu ZN, et al. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology 2006;186(4):572-8
-
(2006)
Psychopharmacology
, vol.186
, Issue.4
, pp. 572-578
-
-
Wu, R.R.1
Zhao, J.P.2
Liu, Z.N.3
-
60
-
-
0344033647
-
A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse
-
Beasley CMJ, Sutton VK, Hamilton SH, et al. A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. J Clin Psychopharmacol 2003;23(6):582-94
-
(2003)
J Clin Psychopharmacol
, vol.23
, Issue.6
, pp. 582-594
-
-
Beasley, C.M.J.1
Sutton, V.K.2
Hamilton, S.H.3
-
61
-
-
34748881146
-
Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics
-
Chrome L, Holt RI, Zachry WM, et al. Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics. Ann Pharmacother 2007;41(10):1593-603
-
(2007)
Ann Pharmacother
, vol.41
, Issue.10
, pp. 1593-1603
-
-
Chrome, L.1
Holt, R.I.2
Zachry, W.M.3
-
62
-
-
33748749787
-
The early effect of olanzapine and risperidone on insulin secretion in atypical-naive schizophrenic patients
-
Chiu CC, Chen KP, Liu HC, et al. The early effect of olanzapine and risperidone on insulin secretion in atypical-naive schizophrenic patients. J Clin Psychopharmacol 2006;26(5):504-7
-
(2006)
J Clin Psychopharmacol
, vol.26
, Issue.5
, pp. 504-507
-
-
Chiu, C.C.1
Chen, K.P.2
Liu, H.C.3
-
63
-
-
0036001466
-
Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: An analysis of 45 published cases
-
Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry 2002;14(1):59-64
-
(2002)
Ann Clin Psychiatry
, vol.14
, Issue.1
, pp. 59-64
-
-
Jin, H.1
Meyer, J.M.2
Jeste, D.V.3
-
64
-
-
33746123940
-
Do guidelines for severe mental illness promote physical health and well-being?
-
Citrome L, Yeomans D. Do guidelines for severe mental illness promote physical health and well-being? J Psychopharmacol 2005;19(6 Suppl):102-9
-
(2005)
J Psychopharmacol
, vol.19
, Issue.6 SUPPL.
, pp. 102-109
-
-
Citrome, L.1
Yeomans, D.2
-
65
-
-
0037798919
-
Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics
-
Atmaca M, Kuloglu M, Tezcan E, et al. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 2003;64(5):598-4
-
(2003)
J Clin Psychiatry
, vol.64
, Issue.5
, pp. 598-604
-
-
Atmaca, M.1
Kuloglu, M.2
Tezcan, E.3
-
66
-
-
0035002177
-
A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder
-
Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001;158(5):765-74
-
(2001)
Am J Psychiatry
, vol.158
, Issue.5
, pp. 765-774
-
-
Conley, R.R.1
Mahmoud, R.2
-
67
-
-
35948939626
-
Olanzapine: Interpreting the label change
-
Citrome L. Olanzapine: interpreting the label change. Int J Clin Pract 2007;61(12):1960-2
-
(2007)
Int J Clin Pract
, vol.61
, Issue.12
, pp. 1960-1962
-
-
Citrome, L.1
-
68
-
-
42149146835
-
Interpreting and applying the EUFEST results using number needed to treat: Antipsychotic effectiveness in first-episode schizophrenia
-
Citrome L. Interpreting and applying the EUFEST results using number needed to treat: antipsychotic effectiveness in first-episode schizophrenia. Int J Clin Pract 2008;62(5):837-40
-
(2008)
Int J Clin Pract
, vol.62
, Issue.5
, pp. 837-840
-
-
Citrome, L.1
-
69
-
-
33947430212
-
Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: A population-based Study
-
Yang S-Y, Kao Yang Y-H, Chong M-Y, et al. Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: a population-based Study. Clin Pharmacol Ther 2007;81(4):586-94
-
(2007)
Clin Pharmacol Ther
, vol.81
, Issue.4
, pp. 586-594
-
-
Yang, S.-Y.1
Kao Yang, Y.-H.2
Chong, M.-Y.3
-
70
-
-
40949136198
-
Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: A systematic review
-
Gao K, Kemp DE, Ganocy SJ, et al. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol 2008;28(2):203-9
-
(2008)
J Clin Psychopharmacol
, vol.28
, Issue.2
, pp. 203-209
-
-
Gao, K.1
Kemp, D.E.2
Ganocy, S.J.3
-
71
-
-
40349094467
-
Tardive dyskinesia and new antipsychotics
-
Correll, CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008;21(2):151-6
-
(2008)
Curr Opin Psychiatry
, vol.21
, Issue.2
, pp. 151-156
-
-
Correll, C.U.1
Schenk, E.M.2
-
72
-
-
26644456940
-
Effects of antipsychotic treatment on tardive dyskinesia: A 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study
-
Tenback DE, van Harten PN, Slooff CJ, et al. Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study. J Clin Psychiatry 2005;66(9):1130-3
-
(2005)
J Clin Psychiatry
, vol.66
, Issue.9
, pp. 1130-1133
-
-
Tenback, D.E.1
van Harten, P.N.2
Slooff, C.J.3
-
73
-
-
25144482343
-
Antipsychotic medications and drug-induced movement disorders other than parkinsonism: A population-based cohort study in older adults
-
Lee PE, Sykora K, Gill SS, et al. Antipsychotic medications and drug-induced movement disorders other than parkinsonism: a population-based cohort study in older adults. J Am Geriatr Soc 2005;53(8):1374-9
-
(2005)
J Am Geriatr Soc
, vol.53
, Issue.8
, pp. 1374-1379
-
-
Lee, P.E.1
Sykora, K.2
Gill, S.S.3
-
74
-
-
37849006140
-
Tardive dyskinesia: Minimizing risk and improving outcomes in schizophrenia and other disorders
-
Citrome L, Dufresne R, Dyrud JM. Tardive dyskinesia: minimizing risk and improving outcomes in schizophrenia and other disorders. Am J Manag Care 2007;13(Suppl):1-12
-
(2007)
Am J Manag Care
, vol.13
, Issue.SUPPL.
, pp. 1-12
-
-
Citrome, L.1
Dufresne, R.2
Dyrud, J.M.3
-
75
-
-
37849034195
-
Differences in the effect of second-generation antipsychotics on prolactinaemia: Six weeks open-label trial in female in-patients
-
Svestka J, Synek O, Tomanová J, et al. Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients. Neuro Endocrinol Lett 2007; 28(6):881-8
-
(2007)
Neuro Endocrinol Lett
, vol.28
, Issue.6
, pp. 881-888
-
-
Svestka, J.1
Synek, O.2
Tomanová, J.3
-
76
-
-
51149107891
-
A review of the association between antipsychotic use and hyperprolactinaemia
-
Bushe C, Shaw M, Peveler RC. A review of the association between antipsychotic use and hyperprolactinaemia. J Clin Psychopharmacol 2008;22(2 Suppl):46-55
-
(2008)
J Clin Psychopharmacol
, vol.22
, Issue.2 SUPPL.
, pp. 46-55
-
-
Bushe, C.1
Shaw, M.2
Peveler, R.C.3
-
77
-
-
1442357994
-
Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol
-
Volavka J, Czobor P, Cooper TB, et al. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry 2004;65(1):57-61
-
(2004)
J Clin Psychiatry
, vol.65
, Issue.1
, pp. 57-61
-
-
Volavka, J.1
Czobor, P.2
Cooper, T.B.3
-
78
-
-
51149117634
-
Current guidelines and their recommendations for prolactin monitoring in psychosis
-
Citrome L. Current guidelines and their recommendations for prolactin monitoring in psychosis. J Psychopharmacol 2007;22(2 Suppl):90-7
-
(2007)
J Psychopharmacol
, vol.22
, Issue.2 SUPPL.
, pp. 90-97
-
-
Citrome, L.1
-
79
-
-
0029066856
-
Diabetes, psychological function and male sexuality
-
Schiavi RC, Stimmel BB, Mandeli J, et al. Diabetes, psychological function and male sexuality. J Psychosom Res 1995;39(3):305-14
-
(1995)
J Psychosom Res
, vol.39
, Issue.3
, pp. 305-314
-
-
Schiavi, R.C.1
Stimmel, B.B.2
Mandeli, J.3
-
80
-
-
0028135281
-
Psychotropic medications and their effects on sexual function: Diagnosis, biology, and treatment approaches
-
Gitlin MJ. Psychotropic medications and their effects on sexual function: diagnosis, biology, and treatment approaches. J Clin Psychiatry 1994;55(9):406-13
-
(1994)
J Clin Psychiatry
, vol.55
, Issue.9
, pp. 406-413
-
-
Gitlin, M.J.1
-
81
-
-
51149117097
-
Understanding osteoporosis
-
Javaid MK, Holt RIG. Understanding osteoporosis. J Psychopharmacol 2008;22(2 Suppl):38-45
-
(2008)
J Psychopharmacol
, vol.22
, Issue.2 SUPPL.
, pp. 38-45
-
-
Javaid, M.K.1
Holt, R.I.G.2
-
82
-
-
51149115350
-
Antipsychotics and hyperprolactinaemia: Clinical recommendations
-
Peveler RC, Branford D, Citrome L, et al. Antipsychotics and hyperprolactinaemia: clinical recommendations. J Psychopharmacol 2008;22(2 Suppl):98-103
-
(2008)
J Psychopharmacol
, vol.22
, Issue.2 SUPPL.
, pp. 98-103
-
-
Peveler, R.C.1
Branford, D.2
Citrome, L.3
-
83
-
-
44849105921
-
Effects of olanzapine on slow wave sleep, sleep spindles and sleep-related memory consolidation in schizophrenia
-
Goder R, Fritzer G, Gottwald B, et al. Effects of olanzapine on slow wave sleep, sleep spindles and sleep-related memory consolidation in schizophrenia. Pharmacopsychiatry 2008;41(3):92-9
-
(2008)
Pharmacopsychiatry
, vol.41
, Issue.3
, pp. 92-99
-
-
Goder, R.1
Fritzer, G.2
Gottwald, B.3
-
84
-
-
41549116886
-
A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: Focus on somnolence
-
Gao K, Ganocy SJ, Gajwani P, et al. A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. J Clin Psychiatry 2008;69(2):302-9
-
(2008)
J Clin Psychiatry
, vol.69
, Issue.2
, pp. 302-309
-
-
Gao, K.1
Ganocy, S.J.2
Gajwani, P.3
-
85
-
-
35148822313
-
Atypical antipsychotics, elderly patients, and moraity risk
-
Citrome L. Atypical antipsychotics, elderly patients, and moraity risk. South Med J 2007;100(1):964-5
-
(2007)
South Med J
, vol.100
, Issue.1
, pp. 964-965
-
-
Citrome, L.1
-
87
-
-
0141842769
-
Antipsychocic medication and seizures: A review
-
Hedges D, Jeppson K, Whitehead P. Antipsychocic medication and seizures: a review. Drugs Today 2003;39(7):551-7
-
(2003)
Drugs Today
, vol.39
, Issue.7
, pp. 551-557
-
-
Hedges, D.1
Jeppson, K.2
Whitehead, P.3
-
88
-
-
0038715822
-
Olanzapine induced neuroleptic malignant syndrome - a case review
-
Kogoj A, Velikonja I. Olanzapine induced neuroleptic malignant syndrome - a case review. Hum Psychopharmacol 2003;18(4):301-9
-
(2003)
Hum Psychopharmacol
, vol.18
, Issue.4
, pp. 301-309
-
-
Kogoj, A.1
Velikonja, I.2
-
89
-
-
33746771436
-
Olanzapine-Associated Neuroleptic Malignant Syndrome
-
Norgard NB, Stark JE. Olanzapine-Associated Neuroleptic Malignant Syndrome. Pharmacotherapy 2006;26(8):1180-2
-
(2006)
Pharmacotherapy
, vol.26
, Issue.8
, pp. 1180-1182
-
-
Norgard, N.B.1
Stark, J.E.2
-
91
-
-
0141790782
-
A review of olanzapine-associated toxicity and fatality in overdose
-
Chue P, Singer P. A review of olanzapine-associated toxicity and fatality in overdose. J Psychiatry Neurosci 2003;28(4):253-61
-
(2003)
J Psychiatry Neurosci
, vol.28
, Issue.4
, pp. 253-261
-
-
Chue, P.1
Singer, P.2
-
92
-
-
46949084286
-
Using antipsychotics for the treatment of schizophrenia: Likelihood to be helped or harmed, understanding proximal and distal benefits and risks
-
Citrome L, Kantrowitz J. Using antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks. Expert Rev Neurother 2008;8(7):1079-91
-
(2008)
Expert Rev Neurother
, vol.8
, Issue.7
, pp. 1079-1091
-
-
Citrome, L.1
Kantrowitz, J.2
-
93
-
-
33746115248
-
Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: How can CATIE inform clinicians?
-
Citrome L, Stroup TS. Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians? Int J Clin Pract 2006;60(8):933-40
-
(2006)
Int J Clin Pract
, vol.60
, Issue.8
, pp. 933-940
-
-
Citrome, L.1
Stroup, T.S.2
-
94
-
-
48949120897
-
Reporting outcomes in clinical trials for bipolar disorder: A commentary and suggestions for change
-
Martinez-Arán A, Vieta E, Chengappa KN, et al. Reporting outcomes in clinical trials for bipolar disorder: a commentary and suggestions for change. Bipolar Disord 2008;10(5):566-79
-
(2008)
Bipolar Disord
, vol.10
, Issue.5
, pp. 566-579
-
-
Martinez-Arán, A.1
Vieta, E.2
Chengappa, K.N.3
-
95
-
-
35648936485
-
Reviewing CATIE for clinicians: Balancing benefit and risk using evidence-based medicine tools
-
Karagianis J, Rosenbluth M, Tohen M, et al. Reviewing CATIE for clinicians: balancing benefit and risk using evidence-based medicine tools. Curr Med Res Opin 2007;23(10):2551-7
-
(2007)
Curr Med Res Opin
, vol.23
, Issue.10
, pp. 2551-2557
-
-
Karagianis, J.1
Rosenbluth, M.2
Tohen, M.3
-
96
-
-
57049091477
-
-
Berenson A. Eli Lilly Said to Play Down Risk of Top Pill. New York Times. December 17, 2006. Available from: http://www.nytimes.com/2006/12/ 17/business/17drug.html [Last accessed 2008 Sept 3]
-
Berenson A. Eli Lilly Said to Play Down Risk of Top Pill. New York Times. December 17, 2006. Available from: http://www.nytimes.com/2006/12/ 17/business/17drug.html [Last accessed 2008 Sept 3]
-
-
-
-
97
-
-
34948858402
-
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized Phase 2 clinical trial
-
Patil ST, Zhang L, Martenyi F, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 2007;13(9):1102-7
-
(2007)
Nat Med
, vol.13
, Issue.9
, pp. 1102-1107
-
-
Patil, S.T.1
Zhang, L.2
Martenyi, F.3
|